David Hogg
#179,352
Most Influential Person Now
Researcher
David Hogg's AcademicInfluence.com Rankings
David Hoggphysics Degrees
Physics
#8671
World Rank
#10939
Historical Rank
Cosmology
#313
World Rank
#325
Historical Rank
Astrophysics
#830
World Rank
#887
Historical Rank
Download Badge
Physics
David Hogg's Degrees
- PhD Astrophysics California Institute of Technology
Why Is David Hogg Influential?
(Suggest an Edit or Addition)David Hogg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival with ipilimumab in patients with metastatic melanoma. (2010) (13093)
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) (2731)
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) (1781)
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. (2018) (874)
- Mutations in SUFU predispose to medulloblastoma (2002) (808)
- Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
- Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. (2009) (541)
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. (2017) (459)
- High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. (2006) (401)
- Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents (2006) (384)
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. (2017) (312)
- Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma (1999) (269)
- Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours (2000) (251)
- Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma–pancreatic carcinoma–prone families (2002) (241)
- CDKN2A mutations in multiple primary melanomas. (1998) (227)
- The Y deletion gr/gr and susceptibility to testicular germ cell tumor. (2005) (208)
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. (2017) (201)
- Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study (2017) (169)
- Mutations of the p53 gene do not occur in testis cancer. (1993) (166)
- Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
- Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. (2006) (133)
- Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors (2012) (132)
- Expression of TTK, a novel human protein kinase, is associated with cell proliferation. (1992) (129)
- Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study (2010) (113)
- Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities (2019) (109)
- Genetic testing for melanoma. (2002) (104)
- Melanoma in adolescents: A case‐control study of risk factors in Queensland, Australia (2002) (101)
- Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. (1995) (99)
- Somatic mutations of KIT in familial testicular germ cell tumours (2004) (98)
- Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma (2016) (92)
- Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein-I-related gene product involved in the induction of cell proliferation. (1994) (89)
- Expression of p16 induces transcriptional downregulation of the RB gene (1998) (86)
- Loss of heterozygosity of tumor suppressor genes in testis cancer. (1995) (84)
- Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling (2004) (79)
- Identification, cloning, and characterization of a novel human T-cell-specific tyrosine kinase located at the hematopoietin complex on chromosome 5q. (1993) (79)
- Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2 (2019) (77)
- Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma (2007) (74)
- The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma (2016) (71)
- Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases. (2017) (69)
- Endogenous GABAA and GABAB receptor-mediated electrical suppression is critical to neuronal anoxia tolerance (2011) (65)
- Phenotypic heterogeneity in multiple myeloma families. (2005) (65)
- A phase 2 study of tremelimumab in patients with advanced uveal melanoma (2015) (63)
- Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma (2015) (63)
- Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations (2000) (61)
- Cell cycle dependent regulation of the protein kinase TTK. (1994) (57)
- ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers (2000) (56)
- Germline CDKN2A mutation implicated in predisposition to multiple myeloma. (2000) (56)
- Characterization of the human beta-crystallin gene Hu beta A3/A1 reveals ancestral relationships among the beta gamma-crystallin superfamily. (1986) (50)
- Clinical Features, Treatment, and Outcome in 102 Adult and Pediatric Patients with Localized High-Grade Synovial Sarcoma (2011) (50)
- Malignant melanoma in patients with multiple endocrine neoplasia type 1 and involvement of the MEN1 gene in sporadic melanoma (2000) (50)
- Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs) (2010) (50)
- Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. (2018) (49)
- CDKN2A mutation in a non‐FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein (1997) (48)
- The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. (2010) (46)
- Genetic susceptibility in familial melanoma from northeastern Italy (2004) (45)
- Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients (2016) (45)
- Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas (2018) (43)
- Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. (2019) (43)
- Germline splicing mutations of CDKN2A predispose to melanoma (2003) (40)
- Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors (2008) (39)
- mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study (2014) (39)
- Heterogeneity of risk for melanoma and pancreatic and digestive malignancies (2004) (39)
- 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) (2015) (39)
- A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). (2008) (37)
- Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas. (2001) (37)
- MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability (2005) (36)
- Affected members of melanoma‐prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF (1997) (32)
- Painted Turtle Cortex is Resistant to an in Vitro Mimic of the Ischemic Mammalian Penumbra (2012) (31)
- Retrospective family study of childhood medulloblastoma (2005) (31)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (2011) (31)
- Nucleotide sequence for the cDNA of the bovine beta B2 crystallin and assignment of the orthologous human locus to chromosome 22. (1987) (31)
- A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families (2001) (30)
- Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. (2016) (30)
- IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression. (1994) (30)
- Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab. (2019) (29)
- Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families (2000) (29)
- Scavenging ROS dramatically increase NMDA receptor whole-cell currents in painted turtle cortical neurons (2014) (27)
- Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancer (1999) (27)
- Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. (1997) (26)
- Oxygen-sensitive reduction in Ca2+-activated K+ channel open probability in turtle cerebrocortex (2013) (26)
- Lack of germline CDK6 mutations in familial melanoma (2000) (26)
- Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201) (2019) (26)
- Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy (2021) (26)
- Decreases in mitochondrial reactive oxygen species initiate GABAA receptor‐mediated electrical suppression in anoxia‐tolerant turtle neurons (2015) (25)
- Transmembrane signalling by interleukin 2. (1991) (23)
- Repeat expansion detection analysis of (CAG)n tracts in tumor cell lines, testicular tumors, and testicular cancer families. (1997) (23)
- Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma. (1997) (22)
- PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis (2016) (22)
- 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma (2019) (21)
- Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience (2018) (20)
- Clinical and molecular characterization of patients at risk for hereditary melanoma in southern Brazil. (2008) (19)
- Younger age-at-diagnosis for familial malignant testicular germ cell tumor (2009) (18)
- Development of the Functional Assessment of Cancer Therapy–Immune Checkpoint Modulator (FACT‐ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs (2020) (18)
- Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). (2017) (17)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (2011) (17)
- Localization of a beta-crystallin gene, Hu beta A3/A1 (gene symbol: CRYB1), to the long arm of human chromosome 17. (1986) (16)
- 1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone (2017) (16)
- Oxygen sensitive synaptic neurotransmission in anoxia-tolerant turtle cerebrocortex. (2012) (16)
- Role of the Cyclin-Dependent Kinase Inhibitor CDKN2A in Familial Melanoma (1998) (14)
- Environmental remodelling of GABAergic and glutamatergic neurotransmission: rise of the anoxia-tolerant turtle brain. (2014) (14)
- A novel role of the corticotrophin‐releasing hormone regulating peptide, teneurin C‐terminal associated peptide 1, on glucose uptake into the brain (2018) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. (2012) (13)
- The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry (2007) (13)
- A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds. (2011) (12)
- Proteomic changes in the brain of the western painted turtle (Chrysemys picta bellii) during exposure to anoxia (2015) (12)
- Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218) (2020) (11)
- Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma (2011) (10)
- Endogenous reductions in N‐methyl‐d‐aspartate receptor activity inhibit nitric oxide production in the anoxic freshwater turtle cortex (2008) (9)
- Cancer patients’ experiences with immune checkpoint modulators: A qualitative study (2020) (9)
- Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV (2019) (9)
- Synthetic Peptides as Therapeutic Agents: Lessons Learned From Evolutionary Ancient Peptides and Their Transit Across Blood-Brain Barriers (2019) (9)
- Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
- Familial sarcoma: challenging pedigrees. (2003) (9)
- Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
- COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). (2017) (8)
- Increased treatment-related toxicity subsequent to an anti-PD-1 agent. (2015) (8)
- Familial sarcoma (2003) (7)
- Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma (2012) (7)
- Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). (2017) (7)
- Activity of the Carboxy-Terminal Peptide Region of the Teneurins and Its Role in Neuronal Function and Behavior in Mammals (2019) (6)
- Information Processing in Affective Disorders: Did an Ancient Peptide Regulating Intercellular Metabolism Become Co‐Opted for Noxious Stress Sensing? (2020) (6)
- Search for genetic variants associated with cutaneous malignant melanoma in the Ashkenazi Jewish population (2005) (6)
- Dabrafenib in the treatment of metastatic or unresectable melanoma (2015) (6)
- Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events (2021) (5)
- Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs (2019) (5)
- Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials. (2018) (5)
- Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target (2020) (5)
- Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma. (2020) (5)
- Concurrent acute lymphoblastic leukemia and juvenile pilocytic astrocytoma in a pediatric patient. (2000) (5)
- New treatments for metastatic melanoma (2014) (5)
- Irinotecan and temozolomide in adults with recurrent sarcoma (2015) (5)
- Efficacy and Safety in Key Patient Subgroups of Nivolumab (Nivo) Alone Or Combined with Ipilimumab (Ipi) Versus Ipi Alone in Treatment-Naive Patients with Advanced Melanoma (2015) (5)
- First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO. (2020) (4)
- Characterization of the Human &Crystallin Gene HuOA3/A1 Reveals Ancestral Relationships among the &-Crystallin Superfamily* (2001) (4)
- Genetic Testing in Familial Melanoma : Epidemiologic/Genetic Assessment of Risks and Role of CDKN2A Analysis. (2001) (4)
- CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus (2021) (4)
- Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (2018) (4)
- Mutations of the p 53 Gene Do Not Occur in Testis Cancer 1 (2006) (3)
- Brain radiosurgery and ipilimumab (Ipi) in melanoma brain metastases (MBM) patients: Does an enhanced immune response induce radionecrosis (RN)? (2015) (3)
- Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. (2020) (3)
- Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL) (2016) (3)
- A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS) (2019) (3)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (2011) (3)
- Bilateral extraocular muscles metastases from a choroidal melanoma. (2013) (3)
- Role of elasmobranchs and holocephalans in understanding peptide evolution in the vertebrates: Lessons learned from gonadotropin releasing hormone (GnRH) and corticotropin releasing factor (CRF) phylogenies. (2017) (3)
- A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS). (2013) (2)
- Studies of differentially-expressed genes in human endometrial cancer of various differentiated grades (2007) (2)
- Melanotic neuro-ectodermal tumour of infancy (1983) (2)
- ROS scavenging mimics anoxia by enhancing GABA receptor‐mediated electrical suppression in anoxia‐tolerant turtle cortex (2012) (2)
- Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors (2021) (2)
- Feasibility study of microbial ecosystem therapeutics (MET-4) to evaluate effects of fecal microbiome in patients on immunotherapy (MET4-IO). (2019) (2)
- Evaluation of low-dose CT scans for surveillance in stage I testicular cancer. (2011) (2)
- Phase II study of vorinostat in patients with advanced melanoma. (2010) (2)
- BRAF testing timelines and impact on the starting of systemic treatment. (2021) (2)
- 831P Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp (2022) (1)
- Advances in Brief Patterns of CDKN 2 A Gene Loss in Sequential Oral Epithelial Dysplasias and Carcinomas 1 (2001) (1)
- Anoxia‐mediated elevation in phasic GABAA receptor currents is essential for anoxia‐tolerance in turtle cortex (2011) (1)
- Regulation of skeletal muscle metabolism and contraction performance via teneurin-latrophilin action (2021) (1)
- A retrospective family study of childhood medulloblastoma (Am J Med Genet 134A(4): 399–403) (2005) (1)
- Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED). (2021) (1)
- BM-16INCREASED ACUTE RADIATION EFFECT (ARE) WITH IPILUMUMAB AND RADIOSURGERY IN PATIENTS WITH MELANOMA BRAIN METASTASES. (2014) (1)
- Patients with multiple primary melanomas may have germline CDKN24 mutations and an occult family history of the disease: 467 (1997) (1)
- Patterns of response to anti-PD1 treatment: Comparison of three radiological response criteria and effect on overall survival (OS) in metastatic melanoma patients (MM). (2015) (1)
- Identification , Cloning , and Characterization of a Novel Human T-Cell-Specific Tyrosine Kinase Located at the Hematopoietin Complex on Chromosome 5 q By (2003) (1)
- Chapter 53 – Testicular Cancer (2012) (1)
- Corticotropin-Releasing Hormone Family of Peptides (2014) (1)
- Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma. (2021) (1)
- Abstract CT226: A pilot study of adoptive cell therapy with in vitro educated MART1 T cells in combination with ipilimumab for the treatment of metastatic melanoma (2015) (0)
- 1043P NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma (2021) (0)
- 1128TiPA PHASE II STUDY (NCT01883323) EVALUATING THE INFUSION OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES (TIL) AND LOW-DOSE INTERLEUKIN-2 (IL-2) THERAPY FOLLOWING NON-MYELOABLATIVE LYMPHODEPLETION USING CYCLOPHOSPHAMIDE AND FLUDARABINE IN PATIENTS WITH METASTATIC MELANOMA. (2014) (0)
- Genomic landscape of malignant peripheral nerve sheath tumor (MPNST)-like melanoma. (2020) (0)
- SubacuteCNSDemyelinationafterTreatmentwith Nivolumab for Melanoma (2015) (0)
- Local Tumor Flare Following Radiosurgery and Ipilimumab (Ipi) for Melanoma Brain Metastases: Increased Immune Response? (2016) (0)
- Anoxia‐tolerant Western Painted turtle cortex is also ischemia‐tolerant (2012) (0)
- Gonadotropin-Releasing Hormone (GnRH) and Corticotropin-Releasing Factor (CRF): An Evolutionary History of Interaction (2021) (0)
- 1144P Clinical predictors of therapeutic benefit from anti-PD1 immune checkpoint inhibitors (ICI) in patients (pts) with metastatic uveal melanoma (2020) (0)
- GABA Receptor and KCa Channel-mediated Electrical Suppression in Anoxic Cortical Pyramidal Neurons of the Painted Turtle (Chrysemys picta bellii) (2015) (0)
- Distal extracellular teneurin region (teneurin C-terminal associated peptide; TCAP) possesses independent intracellular calcium regulating actions, in vitro: A potential antagonist of corticotropin-releasing factor (CRF) (2022) (0)
- BioEssays 9/2020 (2020) (0)
- Contributors (2021) (0)
- A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS) (2019) (0)
- The Anoxic Reduction of Mitochondrial ROS Production Leads to Increased GABAergic Interneuron Activity and Electrical Suppression in Turtle Cerebral Cortex (2016) (0)
- Skeletal muscle metabolism and contraction performance regulation by teneurin C-terminal-associated peptide-1 (2022) (0)
- Anoxia‐mediated decrease in whole‐cell conductance and identification of putative background K+‐like currents in anoxia‐tolerant turtle liver (2010) (0)
- Molecular characterization ofhNRP, acDNAencoding ahuman nucleosome-assembly-protein-l-re lated geneproduct involved inthe induction ofcell proliferation (1994) (0)
- Absence of the L37P polymorphism in exon 1 of the CDKN2A gene. (1997) (0)
- Outcomes of non-treatment naive melanoma patients with central nervous system relapse. (2021) (0)
- 1060P Serum metabolomic profiling reveals differences in polyamine and tryptophan metabolites in patients with cutaneous, mucosal and uveal melanoma (2021) (0)
- families from three continents mutations: a GenoMEL study of melanoma-prone Features associated with germline CDKN2A (2007) (0)
- nucleosome-assembly-protein-l-related gene product involved in the induction of cell proliferation (2005) (0)
- Genetic predisposition to melanoma (2001) (0)
- 7108 POSTER DISCUSSION Surveillance in Stage I Testicular Cancer – Safety of Low Dose CT Scans (2011) (0)
- - Ttk: Threonine, tyrosine kinase (vertebrates) (1995) (0)
- 856P Characterization of patients with brain metastases from metastatic uveal melanoma (2022) (0)
- 765 Molecular Cloning, Genomic Structure, Mapping and Mutational Analysis of Human Suppressor of Fused (hSu[fu]), a Candidate Tumor Suppressor Gene for Medulloblastoma/PNET on Chromosome 10q24.3 (2000) (0)
- Clinical features, treatment, and outcome in 108 patients with localized, high-grade synovial sarcoma (SS). (2016) (0)
- Subject Index Vol. 42, 1986 (1986) (0)
- Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM). (2018) (0)
- T2035 Results of Surveillance for Hereditary Pancreatic Cancer Using Annual MRI(CP) (2008) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Prognosticators of first line treatment for metastatic uveal melanoma (MUM). (2016) (0)
- Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM). (2018) (0)
- Abstract 3141: The relationship between BRAF/NRAS/KIT genomic driver mutations and anti-PD1 immunotherapy responses in patients with advanced melanoma (2019) (0)
- Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy. (2019) (0)
- Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center (2022) (0)
- Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs). (2019) (0)
- 877P Characteristics of malignant cutaneous adnexal tumors in a single-institution study (2022) (0)
- 775P Treatment of Kaposi sarcoma with immune-checkpoint inhibitors: A systematic review and single-arm meta-analysis (2022) (0)
- Efficacy and hepatotoxicity of Infliximab in resolving steroid-refractory immune-related adverse events (irAEs) in a real-world setting. (2020) (0)
- Development of an adoptive cell therapy protocol with tumor-infiltrating lymphocytes and intermediate-dose interleukin-2 therapy (2013) (0)
- extraocular muscle involvement with melanoma metastases (2013) (0)
- 834P Intracranial disease control and survival in patients with melanoma brain metastases (MBM) treated with radiation and immune checkpoint inhibitors (IO) (2022) (0)
- 397PImmune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David Hogg?
David Hogg is affiliated with the following schools:
